UGT1A9 allele nomenclature (view change log)

Allele naming	Protein	Nucleotide change	Amino acid change	Effect	Enzyme activity		Genbank	References	Notes
					In vivo	In vitro
UGT1A9*1a	UGT1A9.1			Wild-type	Normal	Normal	AC019072; AF297093
UGT1A9*1b	UGT1A9.1	-118(dT)9>10			-118 (dT)(9/9) genotype was significantly associated with reduced toxicity and increased response for treatment with a combination of capecitabine plus irinotecan (CPT-11). Carlini et al. 2005	Luciferase activity increased. Yamanaka et al. 2004 No significant change in luciferase activity. No association with hepatic UGT1A9 protein content. Girard et al. 2004	N/A	Yamanaka et al. 2004	Originally named UGT1A9*22
UGT1A9*1c	UGT1A9.1	-440(T>C)/-331(C>T)					N/A	Girard et al. 2004
UGT1A9*1d	UGT1A9.1	-440(T>C)/-331(C>T)/-118(dT)9>10					N/A	Girard et al. 2004
UGT1A9*1e	UGT1A9.1	-87(G>A)					N/A	Girard et al. 2004
UGT1A9*1f	UGT1A9.1	-1818(T>C)/-440(T>C)/-331(C>T)/-118(dT)9>10					N/A	Girard et al. 2004
UGT1A9*1g	UGT1A9.1	-1887(T>G)/ -440(T>C)/-331(C>T)					N/A	Girard et al. 2004
UGT1A9*1h	UGT1A9.1	-1887(T>G)/-665(C>T)/-440(T>C)/-331(C>T)					N/A	Girard et al. 2004
UGT1A9*1j	UGT1A9.1	-1818(T>C)/-440(T>C)/-331(C>T)					N/A	Girard et al. 2004
UGT1A9*1k	UGT1A9.1	-1818(T>C)/-665(C>T)/-440(T>C)/-331(C>T)/-118(dT)9>10					N/A	Girard et al. 2004
UGT1A9*1l	UGT1A9.1	-2152(C>T)/-440(T>C)/-331(C>T)/-275(T>A)				Associated with increased protein expression in the liver Girard et al. 2004	N/A	Girard et al. 2004
UGT1A9*1m	UGT1A9.1	-665(C>T)/-440(T>C)/-331(C>T)/-118(dT)9>10					N/A	Girard et al. 2004
UGT1A9*1n	UGT1A9.1	-2152(C>T)/-665(C>T)/-440(T>C)/-331(C>T)/-275(T>A)				Associated with increased protein expression in the liver Girard et al. 2004	N/A	Girard et al. 2004
UGT1A9*1p	UGT1A9.1	-1818(T>C)/-665(C>T)/-440(T>C)/-331(C>T)					N/A	Girard et al. 2004
UGT1A9*1q	UGT1A9.1	I219 (A>T)/I313 (C>A)/I399 (C>T)			Subject with the I399T allele had approximately 2-fold lower systemic exposure to SN-38. Sandanaraj et al. 2007 I399 polymorphisms do not contribute to interindividual differences in MPA pharmacokinetics. Inoue et al. 2007	I399T is associated with an increased protein expression and SN-38 glucuronidation in the liver Girard et al. 2006		Carlini et al. 2005 Girard et al. 2006
UGT1A9*1r	UGT1A9.1	I152 (G>A)/I219 (A>T)/I313 (C>A)						Carlini et al. 2005
UGT1A9*1s	UGT1A9.1	-87 (G>A)/I219 (A>T)/I313 (C>A)						Carlini et al. 2005
UGT1A9*1t	UGT1A9.1	I143 (C>T)/I152 (G>A)/I219 (A>T)/I313 (C>A)						Carlini et al. 2005
UGT1A9*1u	UGT1A9.1	-118(dT)9>10/I219 (A>T)/I313 (C>A)/I399 (C>T)						Girard et al. 2006
UGT1A9*1v	UGT1A9.1	-5366 (G>T)/ -4549 (T>C)/-2152(C>T)/-275(T>A)/ I219 (A>T)/I313 (C>A)/I399 (C>T)						Girard et al. 2006
UGT1A9*1w	UGT1A9.1	-5366 (G>T)/ -4549 (T>C)/-2152(C>T)/-275(T>A)						Girard et al. 2006
UGT1A9*1x	UGT1A9.1	I190 (T>C)						Fujuta et al. 2006
UGT1A9*2	UGT1A9.2	8(G>A)	C^3Y				AF481811	Villeneuve et al. 2003
UGT1A9*3a	UGT1A9.3	98(T>C)	M^33T			Substrate-dependent impact Villeneuve et al. 2003	AF481810	Villeneuve et al. 2003
UGT1A9*3b	UGT1A9.3	-1818(T>C)/-440(T>C)/-331(C>T)/98(T>C)	M^33T				N/A	Girard et al. 2004
UGT1A9*4	UGT1A9.4	726(T>G)	Y^242X			Truncated protein	N/A	Saeki et al., 2003
UGT1A9*5	UGT1A9.5	766(G>A)	D^256N			Decreased activity Jinno et al. 2003	N/A	Jinno et al. 2003

Changes made on the last updates are in red (2007-09-04 and 2007-10-29).

N/A : data not available in the manuscript